Applicability of PDOX in Patients With Primary Liver Cancer: A Randomized Controlled Trial
This Randomized Controlled Trial was to clarity the clinical feasibility of PDOX results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.
Hepatocellular Carcinoma Resectable
DRUG: Oxaliplatin|DRUG: Doxorubicin|DRUG: Lobaplatin|DRUG: Cisplatin|DRUG: Oxaliplatin, Leucovorin, fluorouracil|DRUG: Lobaplatin, Raltitrexed
The one-year DFS rate, The one-year DFS rate is defined as the percentage of participants who have not accrued disease at the time of 1 year., From the start date of the Treatment until date of the time of 1 year
Adverse events, Number of participants with treatment-related adverse events as assessed by CTCAE v5.0, From the beginning of therapy until the date of death from any cause(max 24 months)
Data of Patients who received PDOX after primary liver cancer radical reaction and received Transarterial Chemoembolization #will be collected

#excluding incomplete data. The primary endpoint was the one-year disease-free survival(DFS) rate #Secondary endpoint was the adverse event.